Company intelligence / Profile preview
Proneuron Biotechnologies
Los Angeles, California, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Proneuron Biotechnologies developed immune-based therapies for neurological conditions such as spinal cord injury and stroke. Their lead candidate demonstrated neuroprotection and enhanced neurogenesis in preclinical models. The company had at least one clinical trial but did not advance programs to late-stage development or commercialization before becoming inactive.
- Therapeutic areas
- Neurology
- Modalities
- ProteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Teva Pharmaceutical IndustriesTamir Capital/Tamir Fishman Ventures
Beyond the preview
Go deeper on Proneuron Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proneuron Biotechnologies.